Regencell Bioscience (NASDAQ:RGC) Trading Up 8.9% – Still a Buy?

Regencell Bioscience Holdings Limited (NASDAQ:RGC)’s stock price was up 8.9% during trading on Thursday . The company traded as high as $29.80 and last traded at $29.09. Approximately 92,156 shares changed hands during mid-day trading, a decline of 87% from the average daily volume of 717,375 shares. The stock had previously closed at $26.72.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Regencell Bioscience in a research note on Monday, December 29th. One analyst has rated the stock with a Sell rating, According to MarketBeat, the company presently has an average rating of “Sell”.

Regencell Bioscience Stock Up 8.6%

The company has a 50-day simple moving average of $26.04 and a 200 day simple moving average of $18.46.

Hedge Funds Weigh In On Regencell Bioscience

Large investors have recently bought and sold shares of the stock. Squarepoint Ops LLC bought a new position in shares of Regencell Bioscience during the 2nd quarter worth about $1,701,000. Geode Capital Management LLC lifted its stake in shares of Regencell Bioscience by 5,637.5% in the second quarter. Geode Capital Management LLC now owns 391,066 shares of the company’s stock valued at $6,664,000 after buying an additional 384,250 shares during the period. Y Intercept Hong Kong Ltd acquired a new stake in Regencell Bioscience during the second quarter worth about $222,000. BNP Paribas Financial Markets bought a new position in Regencell Bioscience during the second quarter valued at about $768,000. Finally, XTX Topco Ltd acquired a new position in Regencell Bioscience in the 3rd quarter valued at approximately $598,000. 0.13% of the stock is currently owned by institutional investors and hedge funds.

About Regencell Bioscience

Regencell Bioscience Holdings Limited operates a Traditional Chinese medicine (TCM) bioscience company. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.